Can Treating Gum Disease Lower Cardiovascular Risk Markers?

DNA from bacteria linked to gum disease has been detected inside human atherosclerotic plaques. That finding gives the mouth-to-artery connection a molecular foothold: it is more than a survey showing that people with periodontitis also have more cardiovascular disease. It still does not prove that gum disease causes heart attacks, or that a dental cleaning prevents one. The evidence becomes most useful when kept at that boundary.

The practical case for treating periodontitis is already straightforward: it protects teeth and periodontal tissue. The cardiovascular evidence adds a plausible systemic benefit. In randomized trials, non-surgical periodontal therapy—usually scaling and root planing—has lowered inflammatory biomarkers and, in one 100-person trial, improved a composite cardiovascular risk score over six months. Those are meaningful intermediate outcomes, not patient outcomes such as myocardial infarction, stroke, or cardiovascular death.

Oral pathogens have been found in arterial plaques

A 2025 systematic review by Dhungana et al. synthesized 58 studies examining the biological links between periodontal and cardiovascular disease. Across the literature, investigators detected Red Complex periodontal pathogens—Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola—as well as Fusobacterium nucleatum in human atheromatous lesions. A separate 2025 systematic review by Bechina et al. also describes P. gingivalis in atheromatous lesions.

Periodontitis can create inflamed, ulcerated gum tissue with access to the bloodstream. The review identifies invasion of periodontal soft-tissue vasculature as the leading proposed route for bacterial translocation. That makes biological sense, but bacterial presence is not a causal verdict. Most detection studies are cross-sectional and involve people with periodontitis. They cannot tell us whether oral bacteria helped initiate plaque, colonized already-diseased tissue, or traveled there because shared factors such as smoking, diabetes, metabolic disease, or inflammatory susceptibility raise risk for both conditions.

The missing comparison matters. Without cardiovascular patients who do not have periodontitis, plaque detection studies cannot establish whether these bacteria are specific to active gum disease or appear at lower background levels in atherosclerotic tissue more generally. Finding a fingerprint at a scene is not the same as proving who drove the car.

How gum infection could affect arteries

The proposed mechanisms are detailed, but much of this work comes from cell culture and animal models rather than direct measurement in living human arteries. According to Dhungana and colleagues, P. gingivalis lipopolysaccharides and gingipains can activate NF-κB signaling in vascular endothelial cells. That pathway increases adhesion molecules including ICAM-1 and VCAM-1, which can recruit leukocytes to the vessel wall.

The same review describes gingipain-mediated uncoupling of endothelial nitric oxide synthase. Endothelial nitric oxide normally helps restrain platelet aggregation and vascular inflammation; disrupting that signaling could worsen endothelial function. P. gingivalis may also increase macrophage scavenger-receptor activity while impairing reverse cholesterol transport, conditions that favor lipid-loaded foam cells. T. forsythia's BspA surface protein has been linked to inflammatory cytokine signaling in monocyte-macrophage cells.

These mechanisms explain why the hypothesis deserves serious study. They do not show that any one pathway drives human atherosclerosis, nor do they establish how much plaque burden periodontal treatment can change. Mechanistic plausibility is a reason to run better clinical trials, not a substitute for them.

Periodontal therapy moves inflammatory markers

The clearest controlled result comes from a 2025 parallel-arm randomized trial by Shrivastava et al. The study assigned 100 people with chronic periodontitis to scaling and root planing (50 participants) or delayed treatment (50 participants) and followed them for six months. Compared with the unchanged control group, treated participants reduced C-reactive protein by 31.1%, from 4.5 ± 1.2 to 3.1 ± 0.9 mg/L (between-group p<0.01). IL-6 fell 24.1%, from 5.8 ± 1.5 to 4.4 ± 1.2 pg/mL (p<0.05), and TNF-α fell 28.0%, from 8.2 ± 2.0 to 5.9 ± 1.8 pg/mL (p<0.01).

Those markers matter because chronic systemic inflammation tracks with cardiovascular risk. They are still surrogates. A lower CRP level does not tell us how many heart attacks treatment prevented, because this trial did not measure heart attacks.

The trial also reported a 15.1% reduction in Framingham Risk Score in the treatment group, from 18.5 ± 3.2 to 15.7 ± 2.8, versus essentially no change in delayed-treatment controls, from 18.7 ± 3.4 to 18.6 ± 3.3 (control-group p=0.72; between-group p<0.05). Framingham Risk Score is a validated composite risk estimate, which makes this result more clinically interpretable than a cytokine alone. It remains an estimated risk score, not an observed reduction in cardiovascular events.

The broader review literature points in the same direction. A 2024 systematic review and meta-analysis by Meng et al., a 2025 umbrella review by Shi et al., and a 2025 meta-analysis by Cardisciani et al. each found that professional periodontal treatment can reduce circulating inflammatory biomarkers. Cardisciani and colleagues specifically modeled the time course of TNF-α, IL-1β, IL-6, and hsCRP after professional dental cleaning. This cross-review consistency supports a real biomarker signal, although the underlying trials vary in populations, interventions, comparators, and follow-up.

Lipid findings are interesting, not settled

A 2023 study by Kolte et al. followed 60 people with Stage III periodontitis for six months after non-surgical periodontal therapy. Within the single treatment group, IL-6 fell 35.3%, IL-8 fell 41.6%, total cholesterol fell 7.5%, triglycerides fell 1.78%, LDL cholesterol fell 6.2%, and HDL cholesterol rose 21.8%; the study reported p<0.0001 for these comparisons.

The HDL change is large enough to attract attention, which is precisely why it needs restraint. This was a single-arm pre-post study, not a randomized comparison with a concurrent control group. Regression to the mean, dietary changes, seasonal variation, medication changes, and other time-dependent factors could contribute. The inflammatory findings match the direction of controlled data, but the lipid effect sizes should be treated as hypothesis-generating until a controlled trial replicates them.

Cardiac stress biomarkers broaden the signal

Smaller randomized studies have examined biomarkers beyond CRP and cytokines. In a 2023 explorative randomized controlled trial by Isola et al., 48 people with Stage III periodontitis were assigned to minimal standard oral care (24 participants) or full-mouth scaling and root planing (24 participants), with assessment at six months. The study evaluated NT-proBNP, a biomarker of cardiac wall stress, alongside inflammatory and periodontal measures. The research concept reports that periodontal treatment reduced NT-proBNP, but does not provide an effect estimate or confidence interval.

Another 2023 randomized trial by Isola et al. compared quadrant scaling and root planing with full-mouth disinfection in 46 periodontitis patients and reported reductions in GDF-15 and related circulating biomarkers after treatment at six months. GDF-15 rises in settings including myocardial injury and heart failure, but changing it does not demonstrate prevention of either condition.

People with type 2 diabetes may have the strongest rationale for taking periodontal care seriously as part of risk management. A 2024 meta-analysis by Barbirato et al. pooled 14 randomized trials enrolling 1,223 participants with type 2 diabetes and periodontitis and found moderate-quality evidence that periodontal therapy improved systemic inflammatory and oxidative-stress measures. A separate 2025 double-blind trial tested a synbiotic alongside periodontal therapy in 50 participants with diabetes and periodontal disease. Because that trial evaluated a combined intervention, it cannot isolate the cardiovascular contribution of periodontal therapy alone.

The endpoint that still matters most

Every intervention study described here ends at six months or sooner. Atherosclerosis develops over decades, and periodontitis can recur without maintenance care. No trial in this body of evidence reports myocardial infarction, stroke, major adverse cardiovascular events, or cardiovascular mortality after periodontal treatment.

Meng and colleagues explicitly state that a definitive causal relationship between periodontitis and cardiovascular disease has not been established and that improved biomarkers do not confirm fewer cardiovascular events. That is the correct line to hold. Treat periodontitis because it is a real chronic infection-driven inflammatory disease with well-established oral consequences, and because treatment appears to improve systemic inflammatory risk markers. Keep taking prescribed statins, blood-pressure medication, diabetes treatment, and other evidence-based cardiovascular care. Gum therapy belongs beside those measures, not in their place.

Bottom line: Oral periodontal pathogens have been detected in atherosclerotic tissue, and non-surgical periodontal therapy consistently lowers several cardiovascular risk biomarkers. The best controlled trial found lower CRP, IL-6, TNF-α, and Framingham Risk Score after six months. No available trial shows that periodontal therapy prevents a heart attack or stroke.